Idiopathic Thrombocytopenic Purpura

8
Pipeline Programs
4
Companies
6
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
3
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
ELTROMBOPAG OLAMINEApproved
eltrombopag
Unknown Company
oral2026
Amgen
NPLATEApproved
romiplostim
Amgen
Thrombopoietin Receptor Agonist [EPC]subcutaneous2008

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
1
RomiplostimPhase 31 trial
Active Trials
NCT00508820Completed407Est. Mar 2011
E
EisaiChina - Liaoning
3 programs
1
1
1
EltrombopagPhase 31 trial
BlindedPhase 21 trial
10-mg dose of E5501 2G tabletPhase 11 trial
Active Trials
NCT01549054Completed28Est. Aug 2012
NCT00625443Completed53Est. Oct 2009
NCT01433978Terminated24Est. Sep 2013
Grifols
GrifolsNEW YORK, NY
1 program
1
IGIV3I Grifols 10%Phase 31 trial
Active Trials
NCT00511147CompletedEst. Apr 2014
Sanofi
SanofiPARIS, France
1 program
1
GMA161Phase 11 trial
Active Trials
NCT00244257Terminated10Est. Jul 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiEltrombopag
GrifolsIGIV3I Grifols 10%
AmgenRomiplostim
EisaiBlinded
Eisai10-mg dose of E5501 2G tablet
SanofiGMA161

Clinical Trials (6)

Total enrollment: 522 patients across 6 trials

NCT01433978EisaiEltrombopag

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Start: Mar 2012Est. completion: Sep 201324 patients
Phase 3Terminated
NCT00511147GrifolsIGIV3I Grifols 10%

IGIV Study for Chronic ITP Patients Ages 3-70

Start: May 2008Est. completion: Apr 2014
Phase 3Completed
NCT00508820AmgenRomiplostim

An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

Start: Feb 2005Est. completion: Mar 2011407 patients
Phase 3Completed
NCT00625443EisaiBlinded

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Start: May 2007Est. completion: Oct 200953 patients
Phase 2Completed
NCT01549054Eisai10-mg dose of E5501 2G tablet

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Start: Jan 2012Est. completion: Aug 201228 patients
Phase 1Completed
NCT00244257SanofiGMA161

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Start: Aug 2005Est. completion: Jul 200810 patients
Phase 1Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space